On 14 September 2026, Guangdong Tianyu Semiconductor Co., Ltd. (02658.HK) announced that its Board approved an H share repurchase plan under the general mandate granted by shareholders on 19 May 2026, covering up to 5,899,042 H shares, or 10% of the issued H shares as at the date the mandate was granted, with the repurchase price not exceeding the average closing price over the preceding five trading days by 5% or more.
On 14 September 2026, OneRobotics (Shenzhen) Co., Ltd. (06600.HK) announced that the trustee of its 2026 H Share Incentive Scheme purchased a further 101,200 H shares on the market between 28 August and 14 September 2026 at approximately HKD 39.48 to approximately HKD 53.00 per share, for a total consideration of approximately HKD 5.0 million; following the purchase, the trustee holds 653,200 H shares, representing approximately 0.290% of the total issued H shares.
On 14 September 2026, XIAMEN YAN PALACE BIRD'S NEST INDUSTRY CO., LTD. (01497.HK) announced that it has entered into a product sales and purchase framework agreement with Shenzhen Yan Palace for the sale of bird's nest-related products from 14 September 2026 to 31 December 2028, with annual caps of RMB 6.0 million, RMB 25.0 million and RMB 55.0 million for 2026, 2027 and 2028. A capital increase agreement entered into on the same date will make Shenzhen Yan Palace a connected subsidiary of the Company, rendering the transactions continuing connected transactions subject to the reporting, annual review and announcement requirements but exempt from independent shareholders' approval.
On 14 September 2026, ORANGE SKY G H (01132.HK) announced that Ms. Du Yan has been appointed to replace Ms. Huang Siying as an independent non-executive director, chairman of the remuneration committee of the Board and a member of the audit committee and the nomination committee, with effect from 14 September 2026.
On 14 September 2026, VALUES CULTURAL (01740.HK) announced that Mr. Miao Jian has been appointed as an executive director and co-chief executive officer of the Company with effect from 14 September 2026, and that Ms. Cai Xiaoxin, the current chief executive officer, will serve as co-chief executive officer together with Mr. Miao from the same date.
On 14 September 2026, BOAN BIOTECH (06955.HK) announced that the investigational new drug application for its PD-1/IL-2 antibody-cytokine prodrug BA1203 has been approved by the Centre for Drug Evaluation of the National Medical Products Administration of the PRC, with the drug intended for the treatment of multiple solid tumours.
On 14 September 2026, WEIHAI BANK (09677.HK) announced that the Bank has successfully issued its 2026 green financial bonds (first tranche) in the national interbank bond market, with an issue size of RMB 500 million, a coupon rate of 1.65% and a term of three years.
On 14 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received a Notice of Acceptance from the National Medical Products Administration, with the marketing application for SHR-2004 injection, a Class 1 innovative drug and coagulation factor XI monoclonal antibody, accepted for the proposed indication of preventing venous thromboembolism in adult patients undergoing elective knee replacement surgery, under acceptance number CXSS2600151.
On 14 September 2026, PUBLIC FIN HOLD (00626.HK) announced that Somerley Capital Limited has been appointed as the independent financial adviser, with its opinion letter to be included in the scheme document to be despatched to shareholders; the appointment relates to the proposal to privatise the Company by Public Bank, the Offeror, by way of a scheme of arrangement under Section 99 of the Bermuda Companies Act 1981.
On 14 September 2026, KWAN YONG (09998.HK) issued a positive profit alert stating that the Group is expected to record a net profit attributable to owners of the Company of approximately SGD 19.8 million for the year ended 30 June 2026, compared with approximately SGD 12.8 million for the year ended 30 June 2025.
On 14 September 2026, YIDU TECH (02158.HK) announced that Yidu Cloud (Beijing) Technology Co., Ltd., an affiliate of the Company, received a notice of award and won the bid for the ageing and health innovation translation construction project of the National Clinical Medical Research Centre for Geriatric Diseases of Xiangya Hospital of Central South University, with a total project amount of approximately RMB 3,565,000.
On 14 September 2026, HX COLDCHAIN (01641.HK) announced that it subscribed, using idle funds, for a wealth management product in the amount of RMB 20 million with Bank of Communications Co., Ltd. Hunan Provincial Branch, namely the "Yuntong Wealth" 35-day fixed-term structured deposit with an expected annualised return of 0.65% to 1.58%, constituting a discloseable transaction under the Listing Rules.
On 14 September 2026, CMS (00867.HK) announced that CMS-D001 tablets, an innovative drug, obtained a drug clinical trial approval notice issued by the National Medical Products Administration on 11 September 2026 and received by the Company on 14 September, with the NMPA agreeing to clinical trials evaluating the efficacy and safety of the drug in treating the systemic lupus erythematosus indication.
On 15 September 2026, HUANENG POWER (00902.HK) announced that it has completed the issue of its 2026 twelfth tranche super short-term commercial paper, with an issue amount of RMB 2.5 billion, a term of 68 days, a unit face value of RMB 100 and an issue interest rate of 1.32%.
On 14 September 2026, CHINA COAL (01898.HK) announced that, due to work reassignment, Mr. Feng Jianhua ceased to be the securities affairs representative of the Company, with the work under his responsibility smoothly handed over and no impact on the normal operation of the relevant work of the Company.
On 14 September 2026, CSPC PHARMA (01093.HK) announced that it presented, as an oral presentation at the 2026 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, the Phase I/II clinical study data of SYS6010 combined with Enlangsuba monoclonal antibody for the treatment of previously untreated driver-gene-negative advanced NSCLC, with confirmed objective response rates of 58.9% and 49.2% in the overall population under the two regimens.
